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Abstract
In this paper, we review recent advances in immuno-oncology with particular focus on liver, kidney, and bladder
cancers as discussed at the 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO).
Keywords: Immunotherapy, Checkpoint inhibitors, Cell-based vaccines, Peptide vaccines, Solid tumors
Introduction
The immune system has a role in both protecting against
tumor development and promoting tumor growth in
cancer with these contrasting roles together referred to as
immunoediting [1]. This process involves three de-
fined phases, beginning with the immunosurveillance
(elimination) phase which is characterized by antigen
presentation and T cell activation and the destruction
of nascent tumor cells and control of tumor growth.
The equilibrium phase involves a steady-state between
tumor growth enhancement and inhibition. Finally, in the
escape phase, cancer progression is favored by the out-
growth of tumor cells that can suppress or escape the
immune system.
Immunity can be divided into innate and adaptive
responses. Innate immunity refers to myeloid and
lymphoid cells that exert a rapid effector function, while
adaptive immunity is driven by T- and B-lymphocytes
that express antigen receptors produced by site-specific
somatic recombination. Adoptive immunity has greater
specificity than innate in retaining antigen memory.
The T-cell response is regulated by a balance of activating
and inhibitory signals, with checkpoints to limit an
ongoing immune response and prevent damage to healthy
tissues. Programmed cell death protein 1 (PD-1) and cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4) are
two examples of inhibitory checkpoints. T-regulatory
(Treg) cells are crucially involved in the immune response
to cancer and tumor-infiltrating T-lymphocyte cell (TIL)
density has a positive prognostic association with overall
survival (OS) of patients with various cancer types, in-
cluding advanced ovarian carcinoma, non-small cell
lung (NSCLC), colorectal, breast, head and neck, and
kidney cancer as well as melanoma [2]. Conversely,
Treg infiltration has been reported to predict a poorer
outcome in early-stage NSCLC and renal cell carcinoma.
The approval of sipuleucel-T for the treatment of
prostate cancer was the first immuno-oncology therapy
to be approved. This was followed by the approval of
ipilimumab, an antibody to CTLA-4, for the treatment
of metastatic melanoma in 2011. The anti PD-1 anti-
bodies nivolumab (in melanoma and subsequently
NSCLC) and pembrolizumab in melanoma have also
since been approved, and a large number of immuno-
therapies are being investigated for their potential
activity across many different types of cancer.
Targeting checkpoint and activating pathways is an
evolving approach to cancer therapy and their clinical use
has highlighted a number of important considerations
(Figure). Firstly, immunotherapy agents may be associated
with patterns of response that differ from those seen
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with other treatment modalities (i.e. chemotherapy) and
so their use may require the development of different re-
sponse criteria [3]. For example, a response to CTLA-4 or
PD-1 checkpoint blockade may be observed after an initial
increase in tumor volume caused by the infiltration of
tumor masses through stimulation of immunocompetent
cells. In addition, a reduction in tumor burden may be ob-
served after the appearance of new lesions. These observa-
tions suggest that planned treatment should be continued
regardless of an increase in volume of existing lesions or
the early appearance of new lesions. Moreover, durable
responses may be observed even after cessation of treat-
ment, suggesting an ability of immunotherapy to reset the
equilibrium between host and tumor [4]. Current RECIST
and WHO criteria might not be appropriate to asses these
types of responses and there is a need for new immune-
related response criteria to evaluate these treatments.
Another consideration is that immunotherapies such
as anti-CTLA-4 and anti-PD1 antibodies can act regard-
less of patient characteristics (e.g. age, gender, performance
status, prior therapies) and tumor characteristics (e.g.
histology, mutation status) [5, 6].
Defining predictive biomarkers is currently a major
focus of investigation, in order to better identify those
patients most likely to benefit from treatment. However,
given that immunotherapies are designed to work directly
with the patient’s own immune system rather than directly
targeting the tumor, a different approach to identifying
biomarkers to that which is typically used may be needed.
Various approaches to identify potential biomarkers for
immunotherapies are being evaluated, including expres-
sion of markers related to the target molecule or pathway
(e.g. PD-L1 for therapies directed at the PD-1 pathway),
treatment-emergent changes to the immune system or
tumor microenvironment (e.g. absolute lymphocyte count,
antibody responses to tumor antigens or change in TILs)
and gene expression profiling of the patient or tumor (e.g.
differential tumor expression of immune-related genes).
The unique modes of action of immunotherapeutic
agents can also mean that they are associated with
unique adverse event (AE) profiles as a result of im-
mune system-related activity. These may differ from
those seen with chemotherapy or targeted agents or,
even if the same (e.g. pruritus, diarrhea), their etiology
may differ. As such, different management strategies
are required, including the use of specific algorithms
for immune-related AEs, such as those developed for
ipilimumab.
Another key area of research is the use of various im-
munotherapies in combination with one another and/or
with chemotherapy, targeted agents or radiation. Several
clinical studies have shown that combining different
immunotherapies can improve outcomes and various
combination approaches are being investigated.
The success of novel immunotherapies in melanoma
and other cancers and their activity across multiple
tumor types has led to an increased focus on their po-
tential ability to improve outcomes across a range of
solid and hematological cancers, including those for
which current treatment options are limited and progno-
ses are typically poor. Recent developments in the use of
immunotherapies in liver, kidney, and bladder cancers
were discussed at the 2nd meeting of the Campania
Society of Oncology Immunotherapy (SCITO) and are
reported here.
Hepatocellular carcinoma
Immune response is relevant to the development and
growth of hepatocellular carcinoma (HCC), certain
characteristics of which render it a potential target for
immunotherapeutic intervention. There is an active re-
cruitment of lymphocytes, which have specific mecha-
nisms to recognize and bind to tumor endothelium and
infiltrate tumor tissue, suggesting a potential for cyto-
toxic effector cell activation [7] and there is a correl-
ation between the density of lymphocytic infiltrates in
HCC lesions and prognosis [8]. In HCC patients after
resection, low Tregs in combination with high intratu-
moral activated CD8+ cytotoxic cells was an independent
prognostic factor for both improved disease-free survival
(DFS) and OS [9]. In addition, programmed death-
ligand 1 (PD-L1) overexpression has been shown to
predict recurrence and survival in HCC patients after
resection [10].
Immunotherapeutic strategies can be classified as
either cell-based or non-cell-based. Potential cell-based
approaches include dendritic cell vaccination, cytokine-
induced killer cells, and NK cells or genetically modified
T-cells, while non-cell based strategies include agents in-
clude cytokines (e.g. interferon-[IFN]-α), oncolytic viruses,
peptide vaccines, and checkpoint inhibitor antibodies.
Targeting CTLA-4, PD-1 and PD-L1 with monoclonal
antibodies has revolutionized the field of cancer im-
munotherapy in recent years. Tremelimumab is a fully
humanized IgG2 monoclonal antibody that antagonizes
binding of CTLA-4 to B7 ligands which has shown an-
titumor activity in a variety of murine tumor models
and in melanoma patients after single or multiple doses
[11]. In an investigator-initiated, single-arm pilot phase
II clinical trial conducted at three Spanish hospitals,
tremelimumab showed antitumor and antiviral activity
in HCC patients with chronic hepatitis C virus infection
[12]. A total of 21 patients (mean age 63.5, 71 % male)
with mostly advanced tumors (57 % Barcelona clinic
liver cancer stage C) and varying degrees of liver dysfunc-
tion (43 % Child-Pugh class B) received tremelimumab at
a dose of 15 mg/kg every 90 days for a maximum of four
cycles or until tumor progression or severe toxicity. The
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main endpoint, tumor response, was evaluable in 17 pa-
tients; of these, three patients (18 %) had a partial re-
sponse and 10 patients (59 %) had stable disease, which
in three patients lasted for longer than 6 months. Four
patients had progressive disease. Disease control rate
was 76.4 %. In addition, a >50 % drop in the tumor
marker α-fetoprotein (AFP) was observed in 36 % of
patients with high baseline levels (>100 ng/ml). Median
time to disease progression was 6.48 months (95 %
confidence interval [CI]: 3.95–9.14), which compares
favorably with results obtained with other targeted
agents in HCC (Figure). Median OS was 8.2 months
(95 % CI 4.6 − 21.3), with 12-month survival of 45 %
and 18-month survival of 18 %. Tumor-specific re-
sponses were not tested but specific T-cell responses
against hepatitis C virus antigens were observed in
most patients. Tremelimumab was generally well toler-
ated with fatigue, hyporexia and skin rash (itching)
being the most frequent AEs; most were grade 1−2. In
another feasibility study, tremelimumab is being assessed in
combination with transarterial chemoembolization (TACE)
or radiofrequency ablation (RFA) in patients with HCC pre-
viously treated with sorafenib [13]. To date, 18 patients
have been treated (TACE, n = 8; RFA, n = 10). The most
frequent AE was pruritus and no dose-limiting toxicities
have been reported. One patient developed pulmonitis and
was taken off study but remained disease-free at 16 months.
Anti-PD-1 and PD-L1 agents are also being investi-
gated for their potential role in HCC, with a dose-
escalation phase II clinical trial currently assessing the
safety and efficacy of nivolumab in patients with ad-
vanced HCC with or without chronic viral hepatitis
(NCT01658878).
Another potential approach is the development of pep-
tide vaccines. Tumor-associated antigens are self-derived
proteins rendered immunogenic in tumors by mutation or
aberrant expression. In HCC patients, several tumor-
associated antigens can spontaneously induce CD8+ T-
cell responses including AFP, glypican-3 (GPC-3), and
melanoma-associated gene-A1 (MAGE-A1). Single or
multiple peptides derived from tumor-associated antigens
may be used for cancer vaccination, usually in combination
with an immunomodulatory adjuvant. This approach is be-
ing investigated by the EU-supported HEPAVAC project
(www.hepavac.eu), the aim of which is to develop a univer-
sal vaccine comprising multiple tumor-associated peptides
that are frequently and naturally presented on the surface
of primary HCC cells. Up to 40 of such HLA class I and II
restricted peptides will be selected in a multiepitope and
multi-HLA allele strategy, and used for the induction of
tumor-specific CD4+ T helper cell and cytotoxic CD8+
lymphocyte effector and memory immune responses in
vaccinated patients. In the second stage, this will be
complemented by an additional personalised vaccine
(APVAC), for which mutated peptides will be identified
from tumor lesions on a patient-specific basis and added
to their respective drug compositions. As part of this ini-
tiative, a randomized, open-label, controlled, multicenter
European phase I/II clinical trial will compare tumor re-
section/ablation alone with tumor resection/ablation plus
vaccination.
Further opportunities for improving outcomes in pa-
tients with HCC may be provided by combined immuno-
therapy approaches, which have the potential to be more
successful than single-agent interventions. Preclinical data
suggest combinations of immunostimulatory monoclonal
antibodies in conjunction with vaccines, adoptive T-cell
therapy or conventional therapies (i.e. chemotherapy, tar-
geted biological agents, radiation) are feasible and need to
be clinically investigated. Moreover, evidence in mice with
spontaneous HCC has shown proof of concept for cura-
tive synergistic combinations of an immunostimulatory
antibody triplet combination (PD-L1 + CD137 +OX40) in
conjunction with adoptive T-cell therapy, with extended
survival in a CD8-dependent fashion [14].
Renal cell cancer
The use of targeted agents, in particular vascular endo-
thelial growth factor tyrosine kinase inhibitors (VEGF-
TKIs), has resulted in improved response rates and
progression-free survival (PFS) in patients with meta-
static renal cell cancer (mRCC). However, most patients
progress with maximum PFS generally less than 12 months.
Patients with mRCC present with a variety of immune ab-
normalities, including cellular immune dysfunction, cyto-
kine alterations and antigen presentation defects [15]. In
addition, spontaneous regressions that could be explained
by immune involvement have been observed in patients
with mRCC, further suggesting it may be an immunogenic
cancer type.
Treatment with IFN-α or interleukin-(IL)-2 has pre-
viously shown clinical activity in mRCC with durable
responses being observed in some patients, although
their use has been limited by severe toxicity [16]. A
more promising novel immunotherapeutic strategy in
mRCC is the development of vaccines based on autolo-
gous tumor cells, dendritic cells or peptides. IMA901
is a peptide vaccine consisting of 10 different tumor-
associated peptides that has shown a clinical benefit in
patients with mRCC. In a randomized phase II trial of
68 patients, those who produced an immune response
to two or more of the tumor-associated peptides con-
tained in IMA901 had significantly longer survival
[17]. IMA901 is now being investigated in the ongoing
multicenter phase III IMPRINT trial, which will assess
whether it can prolong OS in patients with metastatic
and/or locally advanced RCC when added to standard
first-line therapy with sunitinib plus cyclophosphamide.
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Another vaccine in development is TroVax (modified
vaccinia Ankara [MVA]-5T4), which consists of an attenu-
ated pox virus vector expressing tumor-associated antigen
5T4. In a randomized, placebo-controlled phase III study
of 733 patients with mRCC, treatment with TroVax in
addition to standard of care was well tolerated but was
not associated with any additional OS benefit when com-
pared with standard of care alone [18]. However, the mag-
nitude of the 5T4-specific antibody response induced by
vaccination with MVA-5T4 was associated with enhanced
patient survival while exploratory analyses suggested that
a number of pre-treatment hematological factors could
potentially be used to identify subsets of patients who
might derive benefit (Figure). AGS-003 is an autologous
dendritic cell vaccine prepared from fully matured and
optimized monocyte-derived dendritic cells, which are co-
electroporated with amplified tumor RNA plus synthetic
CD40L RNA. In a phase II study, AGS-003 in combin-
ation with sunitinib was well tolerated and yielded
supportive immunologic responses and prolonged sur-
vival in patients with mRCC [19]. AGS-003 in combin-
ation with sunitinib is currently being assessed in the
pivotal randomized phase III ADAPT trial. In this study,
patients in the experimental arm are being treated with a
combination of AGS-003 and first-line sunitinib, while the
comparator arm is receiving standard treatment g with
sunitinib alone. After 6 weeks of sunitinib, patients will
receive 8 doses of AGS-003 during the first year and, for
those continuing to benefit, booster doses of AGS-003 will
be given every 3 months thereafter in combination with
standard targeted therapy. The primary endpoint of the
trial is OS.
Anti-PD-1/PD-L1 agents may also have potential utility
in patients with mRCC. In a phase I study, nivolumab had
an objective response rate (ORR) of 29 % and a median
duration of response (DOR) of 56 weeks. Median OS was
not reached at 22 months and 1-year and 2-year OS rates
were 70 % and 52 %, respectively [20]. In a phase II trial,
168 patients with clear-cell mRCC previously treated with
VEGF inhibitors were randomly assigned to nivolumab
0.3, 2, or 10 mg/kg once every 3 weeks [21]. Respective
ORRs were 20 %, 22 %, and 20 %. Median PFS was 2.7,
4.0, and 4.2 months, and median OS was 18.2, 25.5 and
24.7 months, respectively. The most common treatment-
related AE was fatigue (24 %, 22 %, and 35 %, respectively).
Nineteen patients (11 %) experienced grade 3–4 treatment-
related AEs. In a prospective biomarker-based study, nivo-
lumab showed clinical activity in patients with previously
treated and untreated mRCC [22]. CD3+ and CD8 +T-cell
infiltrates increased by a median of 70 % and 88 %
respectively from baseline to day 8 of the second cycle.
Although responses were numerically higher in PD-L1-
positive patients, they were also seen in PD-L1-negative
patients. Changes in biomarkers were consistent with
PD-1 inhibition and provided evidence of immunomodula-
tory effects in serum and in the tumor microenvironment.
As with other tumor types, combined immunotherapy
may offer improved outcomes in mRCC. A combined
CTLA-4 blockade and PD-1 blockade approach was
assessed in the phase I CA209016 study in which pa-
tients with mRCC received nivolumab 3 mg/kg plus
ipilimumab 1 mg/kg (N3 + I1) (n = 21) or nivolumab
1 mg/kg plus ipilimumab 3 mg/kg (N1 + I3) (n = 23)
every 3 weeks for 4 doses followed by nivolumab 3 mg/kg
every 2 weeks until disease progression or unacceptable
toxicity [23]. Treatment-related AEs were seen in 89 % of
patients with grade 3–4 AEs occurring in 43 % of patients.
The most frequent were increased lipase, increased ALT,
diarrhea, colitis, and increased amylase. Overall, the safety
profile was acceptable with only seven patients (N3 + I1: 2;
N1 + I3: 5) discontinued due to any-grade related AE.
Confirmed ORR was 43 % (N3 + I1) and 48 % (N1 + I3),
while median DOR was 31.1 weeks in the N3 + I1 arm
and was not reached in the N1 + I3 arm. PFS at 24 weeks
was 65 % with N3 + I1 and 64 % with N1 + I3.
Another option is combining PD-1 blockade with
VEGFR-TKIs, which may increase the antitumor efficacy
of PD-1 blockade by reducing tumor-infiltrating Tregs
and enhancing the activity of cytotoxic T cells. In the
CA209-016 phase I study, mRCC patients received nivo-
lumab in combination with sunitinib 50 mg (4 weeks on,
2 weeks off ) or pazopanib 800 mg daily, until progres-
sion or unacceptable toxicity [24]. Confirmed ORR was
52 % with sunitinib plus nivolumab and 45 % with pazo-
panib plus nivolumab, while median DOR was 37.1 and
30.1 weeks. PFS at 24 weeks was 78 %, which is com-
parable to sunitinib alone in the first-line treatment of
metastatic RCC. However, dose-limiting liver toxicity in
the pazopanib arm led to its closure. In these studies of
nivolumab with ipilimumab, sunitinib, or pazopanib,
PD-1-positive tumor status did not appear to predict a
response, with significant proportions of PD-L1 nega-
tive patients also responding to treatment. Several other
planned or ongoing trials are also exploring other anti-PD-
1 combination approaches, including with bevacizumab.
Bladder cancer
Metastatic urothelial bladder cancer (UBC) is associ-
ated with limited treatment options and a poor prog-
nosis. Response rates with salvage chemotherapy for
advanced UBC continue to be dismal, generally around
20 % or less, with median OS typically in the region of
6–9 months. UBC is associated with high mutational
complexity, with similar rates of mutation as observed
in patients exposed to tobacco or other environmental
carcinogens, and there is already a precedent for the
use of immune therapy in UBC, with intravesicular
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BCG the standard of care for non-muscle invasive
bladder carcinoma.
Urothelial bladder tumors have been shown to have
levels of PD-1 expression similar to other solid tumors,
with PD-1 expression noted in 45 % of 83 muscle invasive
bladder cancers (Table) [25]. Atezolizumab (MPDL3280A)
is an engineered anti-PD-L1 antibody that inhibits the
binding of PD-L1 to PD-1 and B7.1. In patients with non-
selected solid tumors, including NSCLC, RCC, melanoma,
colorectal cancer and gastric cancer, atezolizumab had an
ORR of 21 % (25/122), with several patients demonstrat-
ing tumor shrinkage within days of initiating treatment
[26]. In a phase I expansion study, 85 previously-treated
patients with metastatic UBC received atezolizumab and
were evaluable for efficacy [27]. Of these, 46 were PD-L1-
positive and 38 were PD-L1-negative, with one having un-
known PD-L1 status. In PD-L1-positive patients, ORR
was 46 % (95 % CI: 31−61 %) compared with 16 % (95 %
CI: 6 − 31 %) in PD-L1-negative patients, with median
response durations not yet reached. Median PFS was
24 weeks (95 % CI: 12 − not reached [NR]) for PD-L1-
positive patients and 8 weeks (95 % CI: 6−12) for PD-
L1-negative patients. OS rates at 24 weeks were 85 %
(95 % CI: 74−96 %) and 71 % (95 % CI: 54−88 %) for
PD-L1-positive or negative patients, respectively, with
medians not yet reached. Drug-related AEs occurred in
64 % of 87 safety-evaluable patients (mostly fatigue,
asthenia or nausea) and 8 % had a grade 3−4 drug-
related AE. Twelve-percent of patients had an immune-
related AE. No treatment-related deaths were observed.
Increases in circulating IFN-γ, IL-18 and activated CD8+
T-cells were observed following treatment. On-treatment
plasma tumor burden markers, but not baseline markers,
were associated with response. Atezolizumab is now being
assessed in patients with UBC in phase II (NCT02108652)
and phase III trials (NCT02302807).
Other anti-PD-1 agents are also being assessed for
bladder cancer. The ongoing KEYNOTE-012 study of
pembrolizumab in PD-L1-positive patients with ad-
vanced solid tumors included a cohort of 33 patients
with recurrent or metastatic UBC [28]. ORR was 24 %
(95 % CI: 10−44 %), with three (10 %) complete and
four (14 %) partial responses. Target lesions were reduced
in 64 % of patients. Six responses were ongoing at a
median duration of follow-up of 11 months and response
duration was 16–40+ weeks (median not reached).
Median PFS was 8.6 weeks (95 % CI: 7.4−14.1) and
median OS was 9.3 months (95 % CI: 3.6–NR) with an
OS rate at 6 months of 58.0 %. Treatment was generally
well tolerated, with only one patient discontinuation due to
a treatment-related AE. A randomized phase III study of
pembrolizumab in advanced UBC is planned (KEYNOTE-
045). Nivolumab is also being investigated as a treatment
for metastatic or unresectable UBC (NCT02387996).
Conclusions
Immunotherapies offer the potential for improving out-
comes in patients with cancer through immune adapt-
ability and memory, while targeting the immune system
rather than the tumor offers the potential for activity
across multiple cancer types irrespective of mutational
status or tumor histology. Their various unique mecha-
nisms of action and safety profiles offer the opportunity
for combination therapy strategies, either with one an-
other and/or together with other treatment modalities.
Such combination approaches have already begun to
show promising results and look likely to offer additional
clinical benefit compared with single-agent therapies.
Although the research focus and main advances have to
date been largely in melanoma, immunotherapies are
being actively investigated in many other cancer types,
including those where treatment options for patients are
limited. Currently ongoing and planned studies should
help bring the benefits of these novel immunotherapies
within the reach of patients with a wide range of cancers.
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